Cantor Fitzgerald initiated coverage on Apellis Pharmaceuticals with a new price target

4/29/25 8:10:45 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Cantor Fitzgerald initiated coverage of Apellis Pharmaceuticals with a rating of Overweight and set a new price target of $44.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$APLS

Date	Price Target	Rating	Analyst
5/9/2025	$23.00	Buy → Neutral	BofA Securities
5/9/2025	$52.00	Strong Buy → Outperform	Raymond James
4/29/2025	$44.00	Overweight	Cantor Fitzgerald
12/17/2024	$36.00	Buy → Neutral	Goldman
11/21/2024	$31.00	Equal-Weight	Morgan Stanley
10/25/2024	$25.00	Sector Perform	RBC Capital Mkts
10/16/2024		Sector Outperform	Scotiabank
10/16/2024		Outperform	William Blair